Lifeward Launches Pilot Program with Ottobock Care to Expand National Access to ReWalk® Personal Exoskeleton

Ottobock Care , one of the leading mobility technology patient care organizations in the U.S. , bring s extensive clinical expertise and patient care infrastructure A dvances Lifeward’s strategy to broaden ReWalk access through capital-efficient channel partner model intended to accelerate growth, expand patient access and improve commercial scalability HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd . (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the launch of a pilot program with Otto b ock Care , one of the leading orthotics and prosthetics patient care organizations in the U.S. The six-month pilot is designed to enable greater patient access to the ReWalk ® 7 Personal Exoskeleton. The agreement brings together Lifeward’s advanced personal exoskeleton technology and Ottobock Care’s established clinical expertise and regional patient care infrastructure. Through the pilot, the companies intend to increase awareness of ReWalk 7 among rehabilitation hospitals and spinal cord injury centers, develop regional clinical and reimbursement expertise, and build sustainable local support for patient evaluation, training and follow-up. In the U.S., Ottobock Care operates more than 50 established patient care clinics nationwide, supported by certified prosthetist-orthotists, clinical liaisons, patient care coordinators and technical specialists. Its care model combines advanced mobility technologies with local clinical expertise and ongoing patient support. “Working with Ottobock Care represents an important step in our strategy to make ReWalk available to more people through highly experienced patient care organizations,” said Mark Grant, President and CEO of Lifeward. “Ottobock Care brings the clinical expertise, regional presence and patient support capabilities needed to accelerate access across the U.S. This pilot is designed to establish a scalable model that could lead to broader national distribution.” "For more than 100 years, the Ottobock family of companies has been committed to helping people achieve greater mobility and independence through innovative technology and exceptional patient care," said Kevin Heidenreich, Head of Patient Services at Ottobock Care. "ReWalk 7 is a compelling addition to the advanced mobility solutions we provide our patients. This pilot gives us the opportunity to deliver cutting-edge technologies alongside exceptional clinical care to promote neuromobility access to more people across the country." About Lifeward Lifeward is a global innovator focused on advancing medical technologies and biomedical solutions that improve lives. The Company’s established portfolio includes market-leading neurorehabilitation technologies such as the ReWalk ® Exoskeleton, AlterG ® Anti-Gravity system, MyoCycle ® FES System, and ReStore ® Exo-Suit. These solutions span the continuum of care in physical rehabilitation and recovery, deploying the most advanced robotics and AI technologies to restore full health and quality of life to a broadening patient population. The Company is now executing a strategic evolution into a diversified biomedical company, expanding beyond rehabilitation and into high-value therapeutic platforms. This includes its Protein Oral Delivery (POD™) platform, designed to enable oral delivery of biologic drugs, with lead candidate ORMD-0801 (oral insulin) targeting a large and underserved diabetes market. Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit G o L ifeward.com . Lifeward ® , ReWalk ® , ReStore ® and Alter G ® are registered trademarks of Lifeward Ltd. and/or its affiliates. Forward-Looking Statements In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements include, among others: management’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the future operations of Lifeward, including research and development activities; the nature, strategy and focus of Lifeward; Lifeward’s ability to successfully integrate Oratech Pharmaceuticals Ltd. into its organization and realize the anticipated benefits therefrom; anticipated clinical drug development activities and related timelines, and other clinical results; the sufficiency of post-transaction resources to support the advancement of Lifeward’s pipeline through certain milestones and the time period over which Lifeward’s post-transaction capital resources will be sufficient to fund its anticipated operations; unexpected costs, charges or expenses resulting from the strategic transaction; expected timing and results of the ORMD-0801 clinical trial; legislative, regulatory, political and economic developments; the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company’s ability to continue to operate as a going concern; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2025 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. Contact: Almog Adar Chief Financial Officer Lifeward E: [email protected] E: [email protected]